Physician profile
Alan R Berg
NPI 1164412425
$371.96
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $17.18 · 2021: $14.46 · 2022: $47.42.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $92.22 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $69.95 | 2019 | |
| Merck Sharp & Dohme LLC | $45.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.63 | 2019 | |
| Astellas Pharma US INC | $33.56 | 2019-2021 | |
| Pfizer INC. | $22.87 | 2019-2022 | |
| Janssen Biotech, INC. | $19.52 | 2019 | |
| Emd Serono, INC. | $18.62 | 2019 | |
| Genzyme Corporation | $17.92 | 2022 | |
| Adaptive Biotechnologies Corporation | $17.86 | 2022 |
4 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.